Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
The Journal of Biological Chemistry
|
June 2, 1995
Phospholipase C rescues visual defect in norpA mutant of Drosophila melanogaster
R R McKay, D M Chen, K Miller, et al.
ESMO Open
|
October 19, 2024
Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer
H Bolek, S C Yazgan, E Yekedüz, et al.
The Biochemical Journal
|
October 24, 2000
Cloning and expression of the human transient receptor potential 4 (TRP4) gene: localization and functional expression of human TRP4 and TRP3
R R McKay, C L Szymeczek-Seay, J P Lievremont, et al.
ESMO Open
|
September 30, 2025
Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis
S C Yazgan, E Yekedüz, E Akkuş, et al.
Urologic Oncology
|
February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503
Raman Jay, R R McKay, L Werner, et al.
Prostate Cancer and Prostatic Diseases
|
August 6, 2014
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer
R R McKay, K A Zukotynski, L Werner, et al.
ESMO Real World Data and Digital Oncology
|
April 22, 2026
Estimate renal cell carcinoma recurrence rates using electronic health records
J Hou, J Wen, R Bhattacharya, et al.
ESMO Open
|
June 20, 2024
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
K Takemura, T Yuasa, A Lemelin, et al.
ESMO Open
|
May 19, 2026
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma
J E Rosenberg, P H O'Donnell, D P Petrylak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 27, 2021
COVID-19 vaccination and breakthrough infections in patients with cancer
A L Schmidt, C Labaki, C-Y Hsu, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
The Journal of Biological Chemistry
|
June 2, 1995
Phospholipase C rescues visual defect in norpA mutant of Drosophila melanogaster
R R McKay, D M Chen, K Miller, et al.
ESMO Open
|
October 19, 2024
Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer
H Bolek, S C Yazgan, E Yekedüz, et al.
The Biochemical Journal
|
October 24, 2000
Cloning and expression of the human transient receptor potential 4 (TRP4) gene: localization and functional expression of human TRP4 and TRP3
R R McKay, C L Szymeczek-Seay, J P Lievremont, et al.
ESMO Open
|
September 30, 2025
Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis
S C Yazgan, E Yekedüz, E Akkuş, et al.
Urologic Oncology
|
February 5, 2017
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015 Oct 1;121(19):3435-43. [Epub 2015 Jun 8]. doi: 10.1002/cncr.29503
Raman Jay, R R McKay, L Werner, et al.
Prostate Cancer and Prostatic Diseases
|
August 6, 2014
Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer
R R McKay, K A Zukotynski, L Werner, et al.
ESMO Real World Data and Digital Oncology
|
April 22, 2026
Estimate renal cell carcinoma recurrence rates using electronic health records
J Hou, J Wen, R Bhattacharya, et al.
ESMO Open
|
June 20, 2024
Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium
K Takemura, T Yuasa, A Lemelin, et al.
ESMO Open
|
May 19, 2026
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma
J E Rosenberg, P H O'Donnell, D P Petrylak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 27, 2021
COVID-19 vaccination and breakthrough infections in patients with cancer
A L Schmidt, C Labaki, C-Y Hsu, et al.
Page
of 3